Breast Cancer Treatment Guidelines

Administration and Dosage

• The American College of Cardiology recommends cardiac monitoring at baseline, 3, 6, and 9 months during treatment for patients receiving Phesgo and docetaxel, with a strength of evidence based on guidelines from 2011 1

Treatment Duration and Outcome

• Phesgo is typically continued for a total of 1 year (up to 18 cycles) or until disease recurrence or unmanageable toxicity in early breast cancer patients, although the specific guideline society is not mentioned in this context 1
• Docetaxel is typically administered for 6 cycles but may be continued longer at physician discretion, with potential dose reductions based on individual patient tolerance, particularly in Asian populations 1

Dose Adjustment and Management

• Docetaxel dose reductions may be necessary based on individual patient tolerance, particularly in Asian populations where higher rates of adverse events have been observed, with a recommendation for dose reductions below 75 mg/m² to manage toxicities 1